Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited (KILITCH) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
kilitch.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41 Cr | 32 Cr | 45 Cr | 33 Cr | 47 Cr | 56 Cr | 61 Cr | 43 Cr | 49 Cr | 54 Cr | 90 Cr | 45 Cr |
| Operating expenses (approx.) | 33 Cr | 30 Cr | 38 Cr | 32 Cr | 41 Cr | 47 Cr | 47 Cr | 40 Cr | 44 Cr | 48 Cr | 67 Cr | 42 Cr |
| EBITDA | 9 Cr | 2 Cr | 7 Cr | 2 Cr | 6 Cr | 9 Cr | 15 Cr | 3 Cr | 5 Cr | 6 Cr | 22 Cr | 3 Cr |
| OPM % | 20.9% | 7.2% | 15.8% | 5.0% | 12.8% | 15.6% | 23.8% | 7.6% | 10.3% | 11.4% | 24.7% | 6.5% |
| Other income | 0.49 Cr | 3 Cr | 0.47 Cr | 3 Cr | 5 Cr | 2 Cr | 2 Cr | 3 Cr | 7 Cr | 2 Cr | 0.49 Cr | 3 Cr |
| Interest | 2 Cr | 2 Cr | 1 Cr | 2 Cr | 0.31 Cr | 1 Cr | 2 Cr | 2 Cr | 1 Cr | 1 Cr | 1 Cr | 0.88 Cr |
| Depreciation | 0.82 Cr | 0.81 Cr | 0.93 Cr | 0.85 Cr | 0.60 Cr | 0.81 Cr | 0.85 Cr | 0.84 Cr | 0.86 Cr | 0.94 Cr | 0.98 Cr | 1 Cr |
| Profit before tax | 7 Cr | 3 Cr | 5 Cr | 2 Cr | 10 Cr | 8 Cr | 14 Cr | 3 Cr | 9 Cr | 6 Cr | 20 Cr | 4 Cr |
| Tax % | 24.9% | 38.3% | 30.5% | 93.2% | 16.8% | 31.9% | 26.2% | 34.4% | 14.5% | 22.9% | 26.4% | 49.1% |
| Net profit | 5 Cr | 2 Cr | 4 Cr | 0.11 Cr | 9 Cr | 6 Cr | 10 Cr | 2 Cr | 8 Cr | 4 Cr | 15 Cr | 2 Cr |
| EPS (₹) | ₹2.93 | ₹1.85 | ₹2.24 | ₹0.83 | ₹5.36 | ₹3.71 | ₹6.47 | ₹1.88 | ₹4.97 | ₹2.50 | ₹4.24 | ₹0.83 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 82 Cr | 53 Cr | 69 Cr | 114 Cr | 140 Cr | 154 Cr | 198 Cr | 235 Cr | Sign in for TTM |
| Operating expenses (approx.) | 75 Cr | 53 Cr | 63 Cr | 104 Cr | 122 Cr | 130 Cr | 167 Cr | 199 Cr | Sign in for TTM |
| EBITDA | 7 Cr | 0.20 Cr | 5 Cr | 10 Cr | 18 Cr | 24 Cr | 31 Cr | 37 Cr | Sign in for TTM |
| OPM % | 8.5% | 0.4% | 7.6% | 9.1% | 12.6% | 15.6% | 15.9% | 15.5% | Sign in for TTM |
| Other income | 4 Cr | 4 Cr | 3 Cr | 3 Cr | 3 Cr | 4 Cr | 11 Cr | 11 Cr | Sign in for TTM |
| Interest | 0.38 Cr | 0.72 Cr | 0.75 Cr | 1 Cr | 5 Cr | 6 Cr | 5 Cr | 6 Cr | Sign in for TTM |
| Depreciation | 2 Cr | 2 Cr | 2 Cr | 2 Cr | 4 Cr | 3 Cr | 3 Cr | 4 Cr | Sign in for TTM |
| Profit before tax | 9 Cr | 2 Cr | 5 Cr | 10 Cr | 12 Cr | 19 Cr | 34 Cr | 39 Cr | Sign in for TTM |
| Tax % | 55.4% | 47.6% | 26.4% | 35.4% | 31.1% | 29.9% | 27.7% | 23.7% | Sign in for TTM |
| Net profit | 4 Cr | 0.84 Cr | 4 Cr | 6 Cr | 8 Cr | 14 Cr | 25 Cr | 30 Cr | Sign in for TTM |
| EPS (₹) | ₹2.61 | ₹0.55 | ₹2.37 | ₹4.73 | ₹6.71 | ₹9.17 | ₹16.60 | ₹8.91 | Sign in for TTM |
| Dividend payout % | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 15 Cr | 15 Cr | 15 Cr | 16 Cr | 16 Cr | 16 Cr | 16 Cr | 35 Cr |
| Reserves | 106 Cr | 103 Cr | 112 Cr | 124 Cr | 136 Cr | 160 Cr | 186 Cr | 245 Cr |
| Borrowings | 9 Cr | 13 Cr | 15 Cr | 20 Cr | 22 Cr | 32 Cr | 49 Cr | 89 Cr |
| Other liabilities | 11 Cr | 10 Cr | 59 Cr | 49 Cr | 47 Cr | 33 Cr | 63 Cr | 92 Cr |
| Total liabilities | 144 Cr | 143 Cr | 203 Cr | 210 Cr | 220 Cr | 240 Cr | 313 Cr | 458 Cr |
| Fixed assets (net) | 9 Cr | 9 Cr | 8 Cr | 43 Cr | 44 Cr | 42 Cr | 46 Cr | 49 Cr |
| CWIP | 20 Cr | 30 Cr | 65 Cr | 3 Cr | 4 Cr | 6 Cr | 47 Cr | 140 Cr |
| Investments | 53 Cr | 52 Cr | 60 Cr | 71 Cr | 62 Cr | 72 Cr | 72 Cr | 75 Cr |
| Inventories | 5 Cr | 6 Cr | 4 Cr | 5 Cr | 2 Cr | 4 Cr | 15 Cr | 12 Cr |
| Trade receivables | 19 Cr | 16 Cr | 23 Cr | 41 Cr | 54 Cr | 63 Cr | 85 Cr | 120 Cr |
| Cash & bank | 8 Cr | 3 Cr | 13 Cr | 10 Cr | 20 Cr | 19 Cr | 10 Cr | 16 Cr |
| Other assets | 29 Cr | 28 Cr | 31 Cr | 36 Cr | 34 Cr | 34 Cr | 38 Cr | 47 Cr |
| Total assets | 144 Cr | 143 Cr | 203 Cr | 210 Cr | 220 Cr | 240 Cr | 313 Cr | 458 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 6 Cr | 3 Cr | -0.15 Cr | 18 Cr | 24 Cr |
| Cash from investing | — | — | — | -15 Cr | 8 Cr | -10 Cr | -40 Cr | -100 Cr |
| Cash from financing | — | — | — | 7 Cr | -0.72 Cr | 9 Cr | 13 Cr | 82 Cr |
| Net cash flow | — | — | — | -2 Cr | 10 Cr | -0.88 Cr | -9 Cr | 6 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -2 Cr | -1 Cr | -0.15 Cr | 18 Cr | -76 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 6.8% | 2.0% | 4.6% | 7.8% | 9.8% | 12.2% | 15.8% | 12.1% |
| ROE % | 3.1% | 0.7% | 2.9% | 5.3% | 6.9% | 8.3% | 13.3% | 10.9% |
| Debtor days | 86 | 109 | 122 | 132 | 142 | 149 | 156 | 186 |
| Inventory days | 36 | 68 | 36 | 28 | 10 | 18 | 53 | 34 |
| Days payable | 33 | 87 | 539 | 238 | 200 | 118 | 186 | 232 |
| Cash conversion cycle | 89 | 90 | -381 | -79 | -48 | 50 | 22 | -13 |
| Debt / equity | 0.08 | 0.11 | 0.12 | 0.15 | 0.15 | 0.18 | 0.25 | 0.32 |
| Current ratio | 3.23 | 2.54 | 1.10 | 1.65 | 1.84 | 2.27 | 2.06 | 1.83 |
| Net debt / EBITDA | 0.22 | 0.00 | 0.00 | 0.00 | 0.13 | 0.53 | 1.26 | 1.99 |
Compare with peers
Loading peers…